XFOR Stock Analysis: Buy, Sell, or Hold?
XFOR - X4 Pharmaceuticals, Inc. Common Stock
$4.13
0.00 (0.12%)
▲
5d:
+1.1%
30d:
+2.1%
90d:
+1.35%
BUY
HIGH Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When XFOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: XFOR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: XFOR shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: XFOR is currently trading at $4.12, which is considered slightly high relative to its 30-day fair value range of $3.81 to $4.14.
Technical Outlook: Technically, XFOR is in a uptrend. Immediate support is located at $3.66, while resistance sits at $4.36.
Market Sentiment: XFOR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.75 (+185.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XFOR is in a uptrend. Immediate support is located at $3.66, while resistance sits at $4.36.
Market Sentiment: XFOR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.75 (+185.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.81 -
$4.14
Company Quality Score
60/100
(HOLD)
Options IV Signal
20th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- BULLISH: Options cheap (IV 20th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 185.2% below Wall St target ($11.75)
Trading Range Analysis
30-Day Trading Range
$3.81 -
$4.14
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.55
(13.4%)
Support & Resistance Levels
Support Level
$3.66
Resistance Level
$4.36
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.51
Wall Street Target
$11.75
(+185.2%)
Revenue Growth (YoY)
-90.6%
Share & Embed Analysis
Last updated: June 23, 2026 1:02 PM ET
Data refreshes hourly during market hours. Next update: 2:02 PM
Data refreshes hourly during market hours. Next update: 2:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XFOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 64 BUY |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
